Content dedicated only to Investor Relationsback to cytosorbents.com

Investor Relations

Overview

CytoSorbents Investor Relations

CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with >270,000 CytoSorb devices sold in 70+ countries to date, and with applications to FDA and Health Canada for DrugSorb-ATR marketing approval under review.

Read More

Featured News

CytoSorbents

Press Release

08 Sep '25

CytoSorbents To Host Global Webinar on “Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb” in Recognition of World Sepsis Day

PRINCETON, N.J., Sept. 8, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, details its upcoming World Sepsis Day Global Webinar, entitled, “Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb” to be held ... CytoSorbents To Host Global Webinar on “Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb” in Recognition of World Sepsis Day

05 Sep '25

CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference

PRINCETON, N.J., Sept. 5, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in one-on-one meetings with investors at the H.C. Wainwright 27th Annual Global Investment Conference at the Lotte New York Palace ... CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference

20 Aug '25

CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR

FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization PRINCETON, N.J., Aug. 20, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, ... CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR

07 Aug '25

CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update

PRINCETON, N.J., Aug. 7, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2025, and recent business highlights.  Second Quarter 2025 Financial Results Revenue was $9.6 million, an ... CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update

View All News

Voices around the world

Next Video

Meet the Leaders of CytoSorbents

View All Leaders